Antibodies against monocyte chemotactic proteins
AssigneeBiogen Idec MA Inc.
InventorsANTONIN R. DE FOUGEROLLES, VICTOR E. KOTELIANSKI, CARL REID, ELLEN GARBER
Life of this patent
Estimating the term…
Abstract
The invention provides antibodies that bind to a plurality of β-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides cells producing the antibodies, and methods of making and using the same.
Claims27
1-59. (canceled)
A method of reducing chemotaxis in a subject suffering from glomerulonephritis, scleroderma, cirrhosis, atherosclerosis, inflammatory bowel disease or rheumatoid arthritis, comprising administering to the subject an isolated antibody or fragment thereof capable of inhibiting chemotaxis in the subject, wherein said antibody or fragment thereof binds a plurality of β-chemokines, wherein said plurality of β-chemokines comprise MCP-1 and at least one other β-chemokine, wherein said antibody or antigen-binding fragment comprises:
- a) a heavy chain variable region having a CDR1 domain comprising the sequence set forth in SEQ ID NO:29, a CDR2 domain comprising the sequence set forth in SEQ ID NO:30, and a CDR3 domain comprising the sequence set forth in SEQ ID NO:
- 31;
- and
- b) a light chain variable region having a CDR1 domain comprising the sequence set forth in SEQ ID NO:32, a CDR2 domain comprising the sequence set forth in SEQ ID NO:33, and a CDR3 domain comprising the sequence set forth in SEQ ID NO:34
- wherein the isolated antibody is administered in an amount sufficient to reduce the chemotactic activity of at least one of MCP-1, MCP-2, or MCP-3.
A method of reducing chemotaxis in a subject suffering from glomerulonephritis, scleroderma, cirrhosis, atherosclerosis, inflammatory bowel disease or rheumatoid arthritis, comprising administering to the subject an isolated antibody or antigen-binding fragment thereof capable of inhibiting chemotaxis in the subject, wherein said antibody comprises a heavy chain variable region complementarity determining region (CDR) from an antibody heavy chain variable region set forth in SEQ ID NO:27, wherein the isolated antibody is administered in an amount sufficient to reduce the chemotactic activity of at least one of MCP-1, MCP-2, or MCP-3.
A method of reducing chemotaxis in a subject suffering from glomerulonephritis, scleroderma, cirrhosis, atherosclerosis, inflammatory bowel disease or rheumatoid arthritis, comprising administering to the subject an isolated antibody or antigen-binding fragment thereof capable of inhibiting chemotaxis in the subject, wherein said antibody comprises a light chain variable region complementarity determining region (CDR) from an antibody light chain variable region as set forth in SEQ ID NO:28, wherein the isolated antibody is administered in an amount sufficient to reduce the chemotactic activity of at least one of MCP-1, MCP-2, or MCP-3.
A method of reducing chemotaxis in a subject suffering from glomerulonephritis, scleroderma, cirrhosis, atherosclerosis, inflammatory bowel disease or rheumatoid arthritis, comprising administering to the subject an isolated single-chain antibody antigen-binding fragment capable of inhibiting chemotaxis in the subject, wherein said single-chain antibody fragment specifically binds MCP-1 and at least one other monocyte chemotactic protein, wherein said single-chain antibody comprises a heavy chain variable region complementarity determining region (CDR) from an antibody heavy chain variable region set forth in SEQ ID NO:27 or a light chain variable region complementarity determining region (CDR) from an antibody light chain variable region set forth in SEQ ID NO:28, wherein said single-chain antibody fragment does not have agonistic chemotactic activity for MCP-2, wherein the isolated single-chain antibody fragment is administered in an amount sufficient to reduce the chemotactic activity of at least one of MCP-1 or MCP-3.
A method of reducing chemotaxis in a subject suffering from glomerulonephritis, scleroderma, cirrhosis, atherosclerosis, inflammatory bowel disease or rheumatoid arthritis, comprising administering to the subject an isolated antibody or fragment thereof capable of blocking chemotaxis, wherein said antibody or antigen-binding fragment comprises:
- a) a heavy chain variable region having a CDR1 domain comprising the sequence set forth in SEQ ID NO:29, a CDR2 domain comprising the sequence set forth in SEQ ID NO:30, and a CDR3 domain comprising the sequence set forth in SEQ ID NO:31;
- and
- b) a light chain variable region having a CDR1 domain comprising the sequence set forth in SEQ ID NO:32, a CDR2 domain comprising the sequence set forth in SEQ ID NO:33, and a CDR3 domain comprising the sequence set forth in SEQ ID NO:34,
- wherein the isolated antibody is administered in an amount sufficient to reduce the chemotactic activity of at least one of MCP-1, MCP-2, or MCP-3.
Dependencies are inferred from the claim text.